Innovative Therapies for Red Cell and Iron related disorders

08:30 - 10:30

Session I - Hematopoietic Stem Cell (HSC) Therapies
Allogeneic BMT in Sickle cell anemia
BMT versus CB-HSC in hemoglobinopathies
New Trends in HSC therapies
Panel Discussion
Selected oral presentations (15 min each)

Chair: F Locatelli (Pavia)
F Bernaudin (Creteil)
S Hongeng (Bankok)
F Locatelli (Pavia)

10:30 - 11:00

Coffee break

11:00 - 13:00

Session II - From HSC to Erythocyte
Expansion of HSCs
The molecular switching in erythroid differentiation
Programming the hemoglobin genes for therapies
Selected oral presentations (15 min each)

Chair: F Grosveld (Rotterdam)
K Humphries (Vancouver)
S Orkin (Boston)
F Grosveld (Rotterdam)
C Baum (Hannover)

13:00 - 15:00

Lunch

15:00 - 17:30

Session III - Gene Therapy -
Gene Therapy of hemoglobin disorders
Design of lentiviral vectors
Oncogenic safety
Selected oral presentations (15 min each)

Chair: P Leboulch (Fontenay/Boston)
P Leboulch
C Frecha (Lyon)

17:30 - 18:00

Coffee break

18:00 - 19:00

Poster Session I: Biotherapies

08:30 - 10:30

Session IV - Iron regulatory pathway for therapies
Heme and Iron recycling
Role of Hemojuvelin in iron deficiency and overload
The essential role of BMP6 in hepcidin regulation
Selected oral presentations (15 min each)

Chair: C Camaschella (Milano)
C Beaumont (Paris)
C Camaschella (Milano)
MP Roth (Toulouse)

10:30 - 11:00

Coffee break

11:00 - 13:00

Session V - The hepcidin effector pathway for therapies - Chair:
Hepcidin agonists and antagonists
Targeting the hepcidin binding site of ferroportin
Relocating misdistributed iron chelators
Selected oral presentations (15 min each)

Chair: Beaumont (Paris)
E Nemeth (Los Angeles)
I de Domenico (Salt Lake City)
I Cabantchick (Jerusalem)

13:00 - 15:00

Lunch

15:00 - 17:30

Session VI: Innovative therapies for red cell disorders (I)
Erythrocyte acting therapies
Gene active therapies
EPO therapy in hemoglobin disorders
Selected oral presentations (15 min each)

Chair: M Narla (New York)
S Fucharoen (Bangkok)
Y Beuzard (Fontenay)
SL Thein (London)
F Galacteros (Creteil)

18:00 - 19:00

Poster Session II: Iron and erythrocyte targeting therapies

09:00 - 10:00

Session VII: Innovative Therapies for red cell disorders (II)
Vascular acting therapies in Sickle cell disease
Heme oxygenase protects against red cell disorders

Chair: F Galacteros (Creteil)
P-L Tharaux (Paris)
M Soares (Lisbon)

10:00 - 10:30

Coffee break

10:30 - 11:30

Keynote Lecture II
Erythrocyte targeting for therapies in malaria

M Narla (New-York)

End of the meeting